Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy.
Clin Transl Oncol
; 19(2): 219-226, 2017 Feb.
Article
em En
| MEDLINE
| ID: mdl-27371031
ABSTRACT
BACKGROUND/AIM:
First-line bevacizumab-based therapies have been shown to improve clinical outcomes in patients with non-squamous non-small-cell lung cancer (NSCLC). We aimed to descriptively analyse patients with non-squamous NSCLC who received a long-term period of maintenance bevacizumab. PATIENTS ANDMETHODS:
This retrospective study included 104 patients who had already reached a progression-free survival (PFS) of at least 9 months.RESULTS:
Median overall survival and PFS were 30.7 and 15.1 months, respectively. The overall response rate was 83 %. Weight loss ≤5 %, ECOG PS = 0, or low number of metastatic sites seem to be predictive factors of good evolution. The incidence of bevacizumab-related adverse events appeared to be similar as the previous studies.CONCLUSION:
Our findings show that there is a long-term survivor group whom the administration of bevacizumab resulted in a relevant prolongation of response without new safety signals. Due to the population heterogeneity, it was not possible to identify the standardised predictive factors.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Adenocarcinoma
/
Carcinoma de Células Grandes
/
Carcinoma Pulmonar de Células não Pequenas
/
Inibidores da Angiogênese
/
Bevacizumab
/
Neoplasias Pulmonares
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article